Top

Published in:

01-07-2009 | Original Paper

Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II)

Authors: Manami Inoue, Norie Kurahashi, Motoki Iwasaki, Yasuhito Tanaka, Masashi Mizokami, Mitsuhiko Noda, Shoichiro Tsugane, for the Japan Public Health Center-based Prospective Study Group

Published in: Cancer Causes & Control | Issue 5/2009

Abstract

Objective

The association between metabolic factors and hepatocellular carcinoma (HCC) has not been well clarified. We prospectively examined whether metabolic factors predicts the subsequent risk of HCC in the Japan Public Health Center-based Prospective Study Cohort II, in consideration of hepatitis virus infection status.

Methods

A total of 17,590 subjects aged 40–69 participating in a questionnaire and health checkup survey during 1993–1994 were followed for incidence of HCC through 2006. A total of 102 cases of HCC were newly documented. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for metabolic factors controlling for potential confounding factors.

Results

The presence of metabolic factors in the aggregate was associated with a significantly increased risk of HCC, especially with hepatitis virus infection. HCC was positively associated particularly with high glucose (HR = 1.75, CI = 1.11–2.74) and overweight (HR = 2.22, CI = 1.42–3.48). Results were similar when analyses were limited to subjects with HCV infection.

Conclusions

Although metabolic factors in the aggregate may be associated with an increased risk of HCC, the main contributors to this association under HCV infection appear to be overweight and high glucose. Improvement of these factors may be a crucial target in preventing progression to HCC in those with HCV infection.

Available only for authorised users

Lonardo A, Loria P, Carulli N (2008) Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med 3:99–108. doi:10.1007/s11739-008-0127-1 PubMedCrossRef

Bugianesi E (2005) Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther 22(Suppl 2):40–43. doi:10.1111/j.1365-2036.2005.02594.x PubMedCrossRef

Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G (2004) Non-alcoholic fatty liver and insulin resistance: a cause–effect relationship? Dig Liver Dis 36:165–173. doi:10.1016/j.dld.2003.12.008 PubMedCrossRef

El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380. doi:10.1016/j.cgh.2005.12.007 PubMedCrossRef

El-Serag HB, Hampel H, Javadi F (2007) The Editorial Board of the Cancer Statistics in Japan. Cancer statistics in Japan 2007. Foundation for Promotion of Cancer Research (FPFR), Tokyo

Marugame T, Matsuda T, Kamo K, Katanoda K, Ajiki W, Sobue T (2007) Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol 37:884–891. doi:10.1093/jjco/hym112 PubMedCrossRef

Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M et al (1995) Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 22:1027–1033PubMedCrossRef

Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428. doi:10.1016/S0140-6736(05)66378-7 PubMedCrossRef

Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44:293–297. doi:10.1016/j.ejca.2007.11.005 PubMedCrossRef

10.

Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135:111–121. doi:10.1053/j.gastro.2008.03.073 PubMedCrossRef

11.

Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877. doi:10.1001/archinte.166.17.1871 PubMedCrossRef

12.

Kuriki K, Hirose K, Tajima K (2007) Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 16:83–89. doi:10.1097/01.cej.0000228404.37858.40 PubMedCrossRef

13.

Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43:1295–1302. doi:10.1002/hep.21208 PubMedCrossRef

14.

Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194–202. doi:10.1001/jama.293.2.194 PubMedCrossRef

15.

Yuan JM, Govindarajan S, Arakawa K, Yu MC (2004) Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 101:1009–1017. doi:10.1002/cncr.20427 PubMedCrossRef

16.

Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213. doi:10.1053/jhep.2002.36780 PubMedCrossRef

17.

El-Serag HB, Richardson PA, Everhart JE (2001) The role of diabetes in hepatocellular carcinoma: a case–control study among United States Veterans. Am J Gastroenterol 96:2462–2467. doi:10.1111/j.1572-0241.2001.04054.x PubMedCrossRef

18.

Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO (2000) Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92:1096–1099. doi:10.1093/jnci/92.13.1096 PubMedCrossRef

19.

La Vecchia C, Negri E, Decarli A, Franceschi S (1997) Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 73:204–207. doi:10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.0.CO;2-#PubMedCrossRef

20.

Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–539. doi:10.1136/gut.2004.052167 PubMedCrossRef

21.

Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Takahashi I, Chayama K (2008) Risk factors for hepatocellular carcinoma in a Japanese population: a nested case–control study. Cancer Epidemiol Biomarkers Prev 17:846–854. doi:10.1158/1055-9965.EPI-07-2806 PubMedCrossRef

22.

Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr (2004) Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15:35–43. doi:10.1023/B:CACO.0000016573.79453.ba PubMedCrossRef

23.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638. doi:10.1056/NEJMoa021423 PubMedCrossRef

24.

Moller H, Mellemgaard A, Lindvig K, Olsen JH (1994) Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 30A:344–350. doi:10.1016/0959-8049(94)90254-2 PubMedCrossRef

25.

Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK (2005) Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 93:1062–1067. doi:10.1038/sj.bjc.6602819 PubMedCrossRef

26.

Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21. doi:10.1023/A:1008995217664 PubMedCrossRef

27.

Tsugane S, Sobue T (2001) Baseline survey of JPHC study–design and participation rate, Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol 11:S24–S29PubMed

28.

Iida M, Sato S, Nakamura M (2001) Standardization of laboratory test in the JPHC study, Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol 11:S81–S86PubMed

29.

Nakamura M, Sato S, Shimamoto T (2003) Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. J Atheroscler Thromb 10:145–153PubMed

30.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404 PubMedCrossRef

31.

Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition, A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469–480. doi:10.1111/j.1464-5491.2006.01858.x PubMedCrossRef

32.

Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity (2006) New criteria for ‘obesity disease’ in Japan. Circ J 66:987–992. doi:10.1253/circj.66.987

33.

Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2002) Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 40:1656–1659. doi:10.1128/JCM.40.5.1656-1659.2002 PubMedCrossRef

34.

Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (1990) World Health Organization International classification of diseases and health related problem, 10th revision. World Health Organization, Geneva, Switzerland

35.

Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2000) World Health Organization International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva, Switzerland

36.

Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2007) Stata Corporation Stata Statistical Software. Stata Corporation, College Station, TX

37.

Yu MC, Yuan JM (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127:S72–S78. doi:10.1016/j.gastro.2004.09.018 PubMedCrossRef

38.

McIntyre N (1978) Plasma lipids and lipoproteins in liver disease. Gut 19:526–530. doi:10.1136/gut.19.6.526 PubMedCrossRef

39.

Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, Huang CC, Yen MF, Chen TH (2006) A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 30:794–799. doi:10.1038/sj.ijo.0803204 CrossRef

40.

Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C (2006) Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 13:56–61. doi:10.1111/j.1365-2893.2005.00655.x PubMedCrossRef

41.

Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343–1351PubMed

42.

Ono M, Saibara T (2006) Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature. J Gastroenterol 41:725–732. doi:10.1007/s00535-006-1876-0 PubMedCrossRef

43.

Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y (2007) Clinical characteristics of NonBNonC-HCC: comparison with HBV and HCV related HCC. Intervirology 50:24–31. doi:10.1159/000096309 PubMedCrossRef

44.

Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K (2005) The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33:72–76. doi:10.1016/j.hepres.2005.09.007 PubMedCrossRef

45.

Iwasaki M, Otani T, Yamamoto S, Inoue M, Hanaoka T, Sobue T, Tsugane S (2003) Background characteristics of basic health examination participants: the JPHC Study Baseline Survey. J Epidemiol 13:216–225PubMed

46.

Iwasaki M, Yamamoto S, Otani T, Inoue M, Hanaoka T, Sobue T, Tsugane S (2006) Generalizability of relative risk estimates from a well-defined population to a general population. Eur J Epidemiol 21:253–262. doi:10.1007/s10654-006-0004-z PubMedCrossRef

Title: Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II)
Authors: Manami Inoue
Norie Kurahashi
Motoki Iwasaki
Yasuhito Tanaka
Masashi Mizokami
Mitsuhiko Noda
Shoichiro Tsugane
for the Japan Public Health Center-based Prospective Study Group
Publication date: 01-07-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 5/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9287-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

Season of diagnosis and prognosis in breast and prostate cancer

Socioeconomic status in relation to early menarche among black and white girls

Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case–control study

Antioxidant vitamins and the risk of endometrial cancer: a dose–response meta-analysis

Predicting lung cancer death in Africa and Asia: differences with WHO estimates

Case–control study of green tea consumption and the risk of endometrial endometrioid adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer